Importance Within 2 decades of onset, 80% of untreated patients with relapsing-remitting
multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary …

Idiopathic or primary angiitis of the CNS (PACNS) and cerebral amyloid angiopathy (CAA)
are unusual vasculopathies generally regarded as unrelated disorders. A few case reports …

In multiple sclerosis, partial remyelination is conspicuous in many lesions, but widespread
and lasting myelin repair ultimately fails as disability and handicap accumulate. Thus far, the …

Bone marrow-derived mesenchymal stem cells (MSCs) are of therapeutic interest in a variety
of neurological diseases. In this study, we wished to determine whether human MSCs …

Background MS is a complex disease. Perhaps uniquely in neurology its clinical course is
characterised by two quite different clinical phases: the relapsing–remitting phase and a …

Methods: The frequency, nature, relationship to systemic features, value of investigation
findings and outcomes for a cohort of patients with neurosarcoidosis (NS) were studied by …

Current therapies for multiple sclerosis effectively reduce inflammation, but do little in terms
of repair to the damaged central nervous system. Cell-based therapies may provide a new …

Background: CNS lupus is a serious but potentially treatable illness, which, though long
recognized, may still present very difficult diagnostic challenges. We believed that further …

Objective: Oligoclonal band (OCB) negative multiple sclerosis (MS) is well recognised but
uncommon, studied in only a few usually small case series. These reached differing …

Background Alemtuzumab, an anti-CD52 antibody, is proven to be more efficacious than
interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis, but its efficacy …